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RESUMO – Dermatose cinzenta ou eritema discrômico persistente (EDP) é uma síndrome clínica de classificação 
controversa. A condição é rara no Brasil. Foi descrita inicialmente em El Salvador, mas também tem sido encontra-
da em vários países da América do Sul e em outras regiões do mundo. Sua etiologia é desconhecida, porém alguns 
autores acreditam que ela representa uma apresentação difusa de erupção medicamentosa fixa, enquanto outros a 
consideram como uma variante do líquen plano pigmentoso por apresentar achados histopatológicos semelhantes. 
Clinicamente apresenta-se com lesões na forma de numerosas máculas cinza de tamanhos variados. Não há trata-
mento eficaz até o momento, no entanto, os benefícios foram relatados com o uso de clofazimina. Neste relato de 
caso, os autores descrevem um caso de ashy dermatose associada ao uso de inibidores específicos da recaptação da 
serotonina.
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ASHY DERMATOSIS ASSOCIATED WITH ORAL ANTIDEPRESSANTS
ABSTRACT – Ashy dermatosis or erythema dyschromicum perstans (EDP) is a clinical syndrome with a controversial 
classification. The condition is rare in Brazil.  It was initially reported in El Salvador but has also been found in several 
South American countries and in other regions of the world.  Its etiology is unknown; however, some authors believe 
that it represents a diffuse presentation of fixed drug eruption, while others consider it to be a variant of lichen planus 
pigmentosus in view of the similar histopathological findings. Clinically, the condition presents with lesions in the form 
of numerous gray macules of varying sizes. There is no effective treatment to date; however, benefits have been repor-
ted with the use of clofazimine. In this report, the authors describe a case of ashy dermatosis associated with the use of 
serotonin-specific reuptake inhibitors.
KEY-WORDS – Skin diseases; Erythema; Hyperpigmentation; Drug eruptions; Lichen planus.
Conflitos de interesse: Os autores declaram não possuir conflitos de interesse.
No conflicts of interest. 
Revista SPDV 71(1) 2013; Fred Bernardes Filho, Maria Victória Pinto Quaresma Santos,Felipe Nazareth de Matos Pinto de Carvalho, et al.;
Ashy dermatosis caused by antidepressants.
86
Caso Clínico
Suporte financeiro: O presente trabalho não foi suportado por nenhum subsídio ou bolsa. 
No sponsorship or scholarship granted. 
Direito à privacidade e consentimento escrito / Privacy policy and informed consent: Os autores declaram que 
pediram consentimento ao doente para usar as imagens no artigo.
The authors declare that the patient gave written informed consent for the use of its photos in this article.
Recebido/Received – Novembro/November 2012; Aceite/Accepted – Dezembro/December 2012
Correspondência:
Dr. Fred Bernardes Filho
Rua Marquês de Caxias, 9 Centro
24030-050 Niterói, RJ, Brazil
Tel.: +55 21 25426658
Fax: + 55 21 25444459
E-mail: f9filho@gmail.com
INTRODUCTION
Ashy dermatosis or erythema dyschromicum perstans 
(EDP) is a hypermelanotic disorder first described by Ra-
mirez in 1957. It is characterized by bluish-grey macules 
that develop on the skin of healthy individuals1,2. It is a 
controversial entity, with some authors considering EDP 
to represent a variant of lichen planus pigmentosus in 
view of the overlapping clinical and histologic features 
of these two conditions. However, according to the lite-
rature, there are significant clinical differences between 
these two dermatoses, giving strength to the hypothesis 
that they represent two separate conditions3,4.
Ashy dermatosis occurs predominantly in dark skin-
ned individuals, principally women. It affects individuals 
of all ages. Most patients present with slowly progres-
sing gray, brownish-gray or bluish-gray macules and 
patches. The presence of an active red border or a pe-
ripheral erythematous margin of 1-2mm in diameter is 
uncommon. The most commonly affected sites are the 
neck, face, trunk and proximal arms, with distribution 
being usually symmetric. No reticular pattern or pruritus 
is found with ashy dermatosis. Although the condition 
may clear up spontaneously, particularly in prepubertal 
children, the lesions usually follow a chronic and insi-
dious course and persist for years in adults. Lichen pla-
nus pigmentosus is characterized by papules, a reticular 
pattern and occasional pruritus, with the lesions affec-
ting sun-exposed and flexural areas. These two derma-
toses are histologically similar; however, according to 
the literature, hyperkeratosis, hypergranulosis and li-
chenoid infiltrate are absent in ashy dermatosis2-6.
Fixed drug eruption is an acute drug reaction that 
improves following withdrawal of the causative drug, 
leaving a residual hyperpigmentation. Several drugs 
may induce fixed pigmented erythema, including chlor-
mezanone, penicillin, acetylsalicylic acid, diclofenac, 
indomethacin, mefenamic acid, ibuprofen, nimesulide, 
clarithromycin, levamisole, phenobarbital and sulfame-
thoxazole-trimethoprim, among others7.
In ashy dermatosis, clinical differential diagnoses 
include, principally, a fixed drug eruption with multiple 
lesions and postinflammatory hyperpigmentation se-
condary to a lichenoid drug eruption, pityriasis rosea, 
small plaque parapsoriasis, Addison's disease, hemo-
chromatosis, lichen planus and erythema multiforme. 
Less common conditions that should be included in a 
differential diagnosis are macular forms of urticaria pig-
mentosa, pinta and leprosy2,7.
Up to the present date, a rigorous epidemiologic 
study examining potential triggers has yet to be perfor-
med. Furthermore, the possibility has been raised that 
some patients with multiple fixed drug eruptions may 
be misdiagnosed as having EDP, emphasizing the need 
to carefully review all medications, including over-the-
-counter drugs and herbal remedies.
CASE REPORT
A 60-year-old Latin-American woman presented at 
an outpatient clinic with dark spots on her abdomen 
that had been present for the preceding 8 months. The 
lesions had gradually progressed to her forehead, back, 
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arms and legs. The patient denied itching, numbness or 
scaling on the lesions. She also reported having been 
in treatment for hypothyroidism for the past 15 years 
and for depression for the past year. Depression was 
initially treated with fluoxetine, this medication being re-
placed by paroxetine hydrochloride after 6 months. The 
patient’s family history revealed nothing of significance. 
Dermatological examination showed numerous con-
fluent bluish-gray macules of varying sizes and shapes 
located on the patient’s neck, abdomen, back and right 
arm (Figs. 1, 2 and 3).  No peripheral erythematous ring 
was present in the lesions. The diagnostic hypotheses 
taken into consideration were fixed drug eruption, ashy 
dermatosis and lichen planus. An incisional biopsy was 
performed on a lesion located on the right arm.  His-
topathology revealed necrotic keratinocytes, pigmenta-
ry incontinence, melanophages and mild perivascular 
mononuclear infiltrate (Fig. 4). Based on the association 
of the clinical manifestations and histopathological fin-
dings, a diagnosis of erythema dyschromicum perstans 
Fig 1 - Numerous confluent bluish-gray macules of varying 
sizes and shapes located on the neck.
Fig 2 - Numerous confluent bluish-gray macules of varying 
sizes and shapes located on the abdomen.
Fig 3 - Numerous confluent bluish-gray macules of varying 
sizes and shapes located on the arm.
Fig 4 - Necrotic keratinocytes, pigmentary incontinence, 
melanophages and mild superficial perivascular mononu-
clear infiltrate.
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was established. The patient was advised to discontinue 
the antidepressant, avoid exposure to the sun and use 
sunscreen regularly.
DISCUSSION
Ashy dermatosis is classified either as a non-infectious 
inflammatory disease or as acquired hyperpigmentation. 
Its etiology is unknown; however, associations with en-
docrinopathies, nematode infestations, exposure to pes-
ticides, HIV infection, vitiligo and chronic hepatitis C, as 
well as an allergy to cobalt and to contrast agents used 
in radiology, have been reported.  It has been associated 
with a wide variety of other diseases, and these diagnos-
tic possibilities can be ruled out on clinical and histologi-
cal grounds.  Histological changes are non-specific, and 
include a thinned epidermis, basal cell vacuolization, 
colloid bodies, perivascular lymphohistiocytic infiltrate, 
pigmentary incontinence and melanophages.
In almost all cases, pigmentation is permanent, al-
though a slight attenuation may occur over many mon-
ths. In general, the treatments proposed in cases of EDP 
are unsuccessful and results are disappointing. They in-
clude protection from the sun, topical corticosteroids, 
retinoids and vitamin C, chemical peels, oral antibiotics, 
vitamin A, dapsone, antimalarial drugs, griseofulvin 
and corticosteroids2,5,7. Based on a case series, clofazi-
mine was reported to be successful for the treatment of 
EDP at a dose of 100mg three times per week for three 
to five months9,10.
Considering the clinical history, dermatological exa-
mination and histopathology of this patient, the present 
report adds one more case to the group of fixed drug 
eruptions.
The low prevalence of this disease in Brazil, together 
with the use of antidepressive drugs as a possible trigge-
ring factor, constitute the two main features that make 
this case uncommon or unique in the medical literature.
REFERENCES
1. Azulay RD, Azulay DR. Discromias. Hipercromias 
adquiridas. In: Azulay DR, editor. Dermatologia. 
5ª Ed. Rio de Janeiro: Guanabara Koogan; 2011. 
p.109-15.
2. Rapela A, Martins S, Bandeira V. Dermatose Cin-
zenta. na Bras Dermatol. 1995; 70(5):437-40.
3. Vega ME, Waxtein L, Arenas R, Hojyo T, Domin-
guez-Soto L. Ashy dermatosis and lichen planus 
pigmentosus: a clinicopathologic study of 31 cases. 
Int J Dermatol. 1992; 31 (2):90-4.
4. Gaertner E, Elstein W. Lichen planus pigmentosus-
-inversus: Case report and review of an unusual 
entity. Dermatol Online J. 2012; 18(2):11.
5. Osswald SS, Proffer LH, Sartori CR. Erythema dys-
chromicum perstans: a case report and review.
Cutis.2001; 68:25-8.
6. Torrelo A, Zaballos P, Colmenero I, Mediero IG, 
Prada I, Zambrano A. Erythema dyschromicum 
perstans in children: a report of 14 cases. J Eur 
Acad Dermatol Venereol. 2005; 19:422-6.
7. Bolognia JL, Jorizzo JL, Rapini RP. Erythema dys-
chromicum perstans. In: Faltam os editors. Derma-
tology. 2th Ed.Falta local de edição: editora; 2008. 
p. 178-9.
8. Tlougan BE, Gonzalez ME, Mandal RV, Kundu RV, 
Skopicki DL. Erythema dyschromicum perstans. 
Dermatol Online J. 2010; 16(11):17.
9. Piquero-Martían J, Pérez-Alfonzo R, Abrusci V, Bri-
ceño L, Gross A, Mosca W, et al. Clinical Trial with 
clofazimine for Treating Erythema Dyschromicum 
Perstans. Int J Dermatol. 1989; 28:198.
10. Baranda L, Torres-Alvarez B, Cortes-Franco R, 
Moncada B, Portales-Perez DP, Gonzalez-Amaro R. 
Involvement of cell adhesion and activation molecu-
les in the pathogenesis of erythema dyschromicum 
perstans (ashy dermatitis). The effect of clofazimine 
therapy. Arch. Dermatol. 1997; 133:325.
Revista SPDV 71(1) 2013; Fred Bernardes Filho, Maria Victória Pinto Quaresma Santos,Felipe Nazareth de Matos Pinto de Carvalho, et al.;
Ashy dermatosis caused by antidepressants.
